drugset / Trial / NCT06336291

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

NCT06336291

Phase 2 Active not recruiting 90 enrolled Philogen S.p.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

Timeline

Start
2024-05-22
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lomustine Small molecule 90 mg/m2
Subject Lomustine Small molecule 110 mg/m2
Subject Onfekafusp alfa Protein / enzyme biologic 7 ug/kg Other
Subject Onfekafusp alfa Protein / enzyme biologic 10 ug/kg Other
Subject Onfekafusp alfa Protein / enzyme biologic 13 ug/kg Other

Indications